Letter to the Editor: Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis

breast cancerbone metastasesbone modifying agentsdrug delivery frequencymeta-analysis

http://ift.tt/2EOH5Bl